Arrowhead Pharmaceuticals (NASDAQ: ARWR) posts Q3 loss but reports strong plozasiran data
Rhea-AI Filing Summary
Arrowhead Pharmaceuticals reported fiscal 2026 third quarter results for the period ended June 30, 2026. Revenue was $75,253 thousand, up from $27,767 thousand a year earlier, while total operating expenses rose to $245,346 thousand, leading to a net loss attributable to Arrowhead of $194,280 thousand, or $(1.36) per diluted share.
Total cash resources, including cash and available-for-sale securities, were $1,566,886 thousand at June 30, 2026, against total liabilities of $1,645,972 thousand, including $682,707 thousand of convertible notes. REDEMPLO® commercial momentum continued, with prescription volume roughly doubling and new marketing authorizations in the EU and Australia.
Topline Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran in severe hypertriglyceridemia showed median triglyceride reductions of 79% and 81%, and a 78% reduction in acute pancreatitis events, including 100% reduction in a highest‑risk subgroup. Arrowhead acquired an FDA priority review voucher and signed a global license for ARO‑PNPLA3 with Madrigal, receiving a $25 million upfront payment and eligibility for up to $975 million in milestones.
Positive
- Transformational plozasiran Phase 3 data: SHASTA-3 and SHASTA-4 achieved 79–81% median triglyceride reductions and a 78% reduction in acute pancreatitis events, with 100% event reduction in the highest‑risk subgroup, supporting a potentially strong efficacy and safety profile.
- REDEMPLO geographic and commercial expansion: Marketing authorizations were granted by the European Commission and Australia’s TGA, and U.S. prescription volume roughly doubled with broadening payer coverage, indicating growing global reach for the FCS franchise.
- Strategic ARO-PNPLA3 out-licensing: The Madrigal Pharmaceuticals deal brings a $25 million upfront payment, up to $975 million in potential milestones, and tiered royalties, monetizing a non-core asset while retaining future upside.
- Robust liquidity: Total cash resources of $1,566,886 thousand at June 30, 2026 provide substantial funding capacity to advance Arrowhead’s RNAi pipeline alongside growing commercial and partnership revenues.
Negative
- None.
Filing Explained
The filing adds a priority-review path and a mid-2027 trial milestone, while reporting 141,135 thousand shares outstanding at June 30, 2026.
This August 4 Form 8-K reports Arrowhead’s completed fiscal 2026 third-quarter results under Item 2.02 and records the company’s reported share count at quarter-end. At
Arrowhead has acquired an FDA priority review voucher and intends to use it with an anticipated severe-hypertriglyceridemia supplemental application before the end of 2026. The filing describes priority review as an FDA action goal of six months versus ten months under standard review, so the voucher creates a potential review-time mechanism rather than an approval of the expanded indication.
Enrollment in the global Phase 3 YOSEMITE trial is complete, but the company anticipates trial completion in mid-2027 and says regulatory applications would follow only if results are successful. That makes mid-2027 trial completion and the subsequent results a named resolution path for this program’s current development stage.
The Madrigal license for ARO-PNPLA3 also includes tiered royalties on commercial sales ranging from high-single digits to mid-teens, in addition to the upfront and milestone amounts already disclosed.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Revenue: $75,253 thousand
Net loss attributable to Arrowhead: $194,280 thousand
Net loss per diluted share: $(1.36)
+5 more
8 metrics
Revenue
$75,253 thousand
Three months ended June 30, 2026
Net loss attributable to Arrowhead
$194,280 thousand
Three months ended June 30, 2026
Net loss per diluted share
$(1.36)
Three months ended June 30, 2026
Total cash resources
$1,566,886 thousand
Cash, cash equivalents, restricted cash and available-for-sale securities at June 30, 2026
Convertible notes, net
$682,707 thousand
Outstanding at June 30, 2026
Madrigal upfront payment
$25 million
Upfront cash under ARO-PNPLA3 license agreement
Potential ARO-PNPLA3 milestones
$975 million
Maximum development, regulatory, and sales milestones payable by Madrigal
Triglyceride reduction SHASTA-3/4
79% and 81%
Median reductions from baseline in Phase 3 plozasiran studies vs placebo
Key Terms
priority review voucher, Orphan Drug Designation, Breakthrough Therapy Designation, RNA interference (RNAi), +2 more
6 terms
priority review voucher regulatory
"acquired a priority review voucher (PRV) that potentially accelerates the process"
A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.
Orphan Drug Designation regulatory
"Orphan Drug Designation by the U.S. FDA for the treatment of patients with FCS"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Breakthrough Therapy Designation regulatory
"was also granted Breakthrough Therapy designation by the U.S. FDA in severe"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
RNA interference (RNAi) medical
"investigational RNA interference (RNAi) therapeutic being developed as a potential"
A natural cellular process in which small RNA molecules shut down the production of a specific protein by blocking the instructions that make it, like flipping a precise light switch to silence one appliance without affecting others. For investors, RNA interference is important because it underpins a class of highly targeted therapies and research tools that can create new drugs, shorten development paths, and change the potential market and regulatory risks for companies working on gene-based treatments.
severe hypertriglyceridemia (sHTG) medical
"plozasiran in patients with severe hypertriglyceridemia (sHTG). Detailed results will"
noncontrolling interest financial
"Net income (loss) attributable to noncontrolling interest, net of tax"
The portion of a business owned by investors other than the controlling owner when one company has control of another; it represents outside shareholders’ share of the subsidiary’s assets and profits. For investors, it matters because those outside claims reduce the amount of profit and net assets attributable to the parent owner — similar to saying part of a pizza belongs to someone else — and thus affects earnings, book value and valuation.
Earnings Snapshot
Revenue: $75,253 thousand
Fiscal 2026 third quarter ended June 30, 2026
Revenue
$75,253 thousand
Increased from $27,767 thousand in the three months ended June 30, 2025.
Net loss attributable to Arrowhead
$194,280 thousand
Compared with a net loss of $175,241 thousand in the prior-year quarter.
Net loss per diluted share
$(1.36)
Worse than $(1.26) per diluted share in the three months ended June 30, 2025.
Total cash resources
$1,566,886 thousand
Up from $781,524 thousand at September 30, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Arrowhead Pharmaceuticals (ARWR) fiscal Q3 2026 financial results?
Arrowhead reported revenue of $75,253 thousand and a net loss attributable to the company of $194,280 thousand, or $(1.36) per diluted share, for the fiscal 2026 third quarter ended June 30, 2026.
How strong were the SHASTA-3 and SHASTA-4 results Arrowhead (ARWR) reported?
The SHASTA-3 and SHASTA-4 Phase 3 studies of plozasiran achieved 79% and 81% median triglyceride reductions and a 78% reduction in acute pancreatitis events, including 100% event reduction in a highest‑risk subgroup.
What progress did Arrowhead (ARWR) report for REDEMPLO in fiscal Q3 2026?
Arrowhead highlighted that U.S. REDEMPLO prescription volume roughly doubled, more than 400 practitioners have prescribed it, major U.S. payers adopted favorable policies, and the drug gained marketing authorizations from the European Commission and Australia’s TGA.
What is included in Arrowhead’s (ARWR) ARO-PNPLA3 deal with Madrigal Pharmaceuticals?
Arrowhead granted Madrigal an exclusive worldwide license to ARO-PNPLA3, receiving a $25 million upfront payment, eligibility for up to $975 million in development, regulatory, and sales milestones, plus tiered royalties on commercial sales.
What is Arrowhead Pharmaceuticals’ (ARWR) cash and debt position as of June 30, 2026?
Arrowhead reported $1,566,886 thousand in total cash resources and total liabilities of $1,645,972 thousand, including $682,707 thousand of convertible notes and a $181,366 thousand credit facility balance at June 30, 2026.
When does Arrowhead (ARWR) expect YOSEMITE, its HoFH trial of zodasiran, to complete?
Arrowhead stated that the global Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia is expected to be completed in mid-2027, after which the company intends to seek regulatory approvals in multiple geographies.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including Zip Code)
(626 ) 304-3400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 4, 2026, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2026 financial results for the period ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release, dated August 4, 2026. | |||||||
| 104 | Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 4, 2026
| ARROWHEAD PHARMACEUTICALS, INC. | ||||||||
| By: | /s/ Daniel Apel | |||||||
| Daniel Apel | ||||||||
| Chief Financial Officer | ||||||||
EXHIBIT 99.1
PRESS RELEASE
August 4, 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET
PASADENA, Calif., August 4, 2026 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results.
“The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is a best-in-class molecule for patients with a spectrum of triglyceride disorders. Based on these promising results, we acquired a priority review voucher (PRV) that potentially accelerates the process of bringing this important new medicine to patients. On the commercial front, REDEMPLO continued to demonstrate growing momentum and penetration with physicians and patients with familial chylomicronemia syndrome. Lastly, we made strong progress across our broad pipeline of RNAi therapeutic candidates at various stages of development, expanding the opportunity to help patients in diverse disease areas.”
Key REDEMPLO® Commercial Events
•U.S. REDEMPLO launch continued to build momentum during the quarter. Key progress included:
◦REDEMPLO prescription volume roughly doubled during the fiscal third quarter.
◦More than 400 unique practitioners have now prescribed REDEMPLO, with the specialty mix led by preventive cardiology and endocrinology.
◦REDEMPLO now has favorable policies in place for the most significant U.S. payers and overall coverage is progressing at a fast trajectory.
•Announced marketing authorizations of REDEMPLO in two new territories:
◦The European Commission (EC) formally granted marketing authorization for REDEMPLO as an adjunct to diet to reduce triglyceride levels in adult patients with FCS. REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical criteria or genetic testing.
◦The Australian Therapeutic Goods Administration (TGA) approved REDEMPLO, as an adjunct to diet to reduce triglyceride levels for adult patients with FCS in Australia.
Key R&D Events
•Announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG). Detailed results will be presented as a HOT LINE Late Breaker at the European Society of Cardiology (ESC) Congress on August 30, 2026.
◦SHASTA-3 and SHASTA-4 successfully met the primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints in both studies.
◦Deep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline were observed in SHASTA-3 and SHASTA-4, respectively.
◦Statistically significant 78% reduction in acute pancreatitis (AP) events versus placebo was observed across the entire sHTG study population, with an unprecedented 100% event reduction in patients with triglycerides above 880 mg/dL and a prior medical history of AP, widely considered to be at the highest risk for AP.
◦Continued and consistent safety and tolerability profile was demonstrated with no new safety signals and a favorable liver safety profile.
•Announced that the Company completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the Company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated low-density lipoprotein cholesterol (LDL-C) and early-onset cardiovascular disease.
◦The Company anticipates that YOSEMITE will be completed in mid-2027 and, pending successful clinical results, intends to seek regulatory approval in multiple geographies thereafter.
◦YOSEMITE was initially designed to enroll 60 participants with HoFH; however, strong global patient and physician interest led to an increase in target enrollment to 70 patients.
•Presented interim results at the European Association for the Study of the Liver Congress (EASL 2026) from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
◦The interim data demonstrate that ARO-INHBE treatment led to clinically meaningful reductions in liver fat as a monotherapy and in combination with low-dose tirzepatide, a GLP-1/GIP receptor co-agonist, in adults with obesity.
•Reported new positive plozasiran clinical data in two oral presentations at the 94th European Atherosclerosis Society (EAS) Congress. The data support plozasiran use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment and suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels through the term of a pregnancy.
Key Corporate Events
•Acquired a U.S. Food and Drug Administration (FDA) priority review voucher, which the company intends to use with its upcoming plozasiran sNDA submission, anticipated before the end of 2026, to potentially expand the approved indication to include patients with severe hypertriglyceridemia (sHTG).
◦A Priority Review designation accelerates FDA’s goal to take action on an application within 6 months, compared to 10 months under standard review.
•Announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, Arrowhead’s clinical stage RNAi therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH).
◦Under the terms of the agreement, Madrigal has made a $25 million upfront payment to Arrowhead. Arrowhead is also eligible to receive development, regulatory, and sales milestone payments of up to $975 million. Arrowhead is further eligible to receive tiered royalties on commercial sales ranging from high-single digits to mid-teens.
◦In a Phase 1 single-ascending dose clinical study, ARO-PNPLA3 achieved encouraging results, including a dose-dependent mean reduction in liver fat of up to 40% in patients homozygous for the I148M mutation, demonstrated no apparent treatment emergent increases in triglycerides or LDL-cholesterol, and had a positive safety and tolerability profile at all doses studied.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BIe3d7a8269de14d348890ebe006a5b6a1. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
Selected Fiscal 2026 Third Quarter Financial Results
ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION
(in thousands, except per share amounts)
| Three months Ended June 30, | |||||||||||
| OPERATING SUMMARY | 2026 | 2025 | |||||||||
| (Unaudited) | |||||||||||
| Revenue | $ | 75,253 | $ | 27,767 | |||||||
| Operating Expenses: | |||||||||||
| Research and development | 198,223 | 162,368 | |||||||||
| Selling, general and administrative | 47,123 | 30,949 | |||||||||
| Total operating expenses | 245,346 | 193,317 | |||||||||
| Operating loss | (170,093) | (165,550) | |||||||||
| Total other expense | (8,812) | (13,539) | |||||||||
| Loss before income tax expense and noncontrolling interest | (178,905) | (179,089) | |||||||||
| Income tax expense (benefit) | 11 | (437) | |||||||||
| Net loss including noncontrolling interest | (178,916) | (178,652) | |||||||||
| Net income (loss) attributable to noncontrolling interest, net of tax | 15,364 | (3,411) | |||||||||
| Net loss attributable to Arrowhead Pharmaceuticals, Inc. | $ | (194,280) | $ | (175,241) | |||||||
| Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted | $ | (1.36) | $ | (1.26) | |||||||
| Weighted-average shares used in calculating - Diluted | 143,378 | 139,039 | |||||||||
| June 30, 2026 | September 30, 2025 | ||||||||||
| FINANCIAL POSITION SUMMARY | (unaudited) | ||||||||||
| Cash, cash equivalents and restricted cash | $ | 19,685 | $ | 88,706 | |||||||
| Available-for-sale securities, at fair value | 1,547,201 | 692,818 | |||||||||
| Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) | 1,566,886 | 781,524 | |||||||||
| Other current and long-term assets | 545,127 | 603,771 | |||||||||
| Total Assets | $ | 2,112,013 | $ | 1,385,295 | |||||||
| Liability related to the sale of future royalties | $ | 392,512 | $ | 367,397 | |||||||
| Credit Facility | 181,366 | 254,883 | |||||||||
| Deferred revenue | 126,339 | 2,399 | |||||||||
| Convertible notes, net | 682,707 | — | |||||||||
| Other liabilities | 263,048 | 257,200 | |||||||||
| Total Liabilities | $ | 1,645,972 | $ | 881,879 | |||||||
| Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity | 465,529 | 466,052 | |||||||||
| Noncontrolling Interest | 512 | 37,364 | |||||||||
| Total Noncontrolling Interest and Stockholders' Equity | $ | 466,041 | $ | 503,416 | |||||||
| Total Liabilities, Noncontrolling Interest and Stockholders' Equity | $ | 2,112,013 | $ | 1,385,295 | |||||||
| Shares Outstanding | 141,135 | 135,702 | |||||||||
About REDEMPLO® (plozasiran)
REDEMPLO (plozasiran) is currently approved by the U.S. Food and Drug Administration, Health Canada, China’s National Medical Products Administration, the Australian Therapeutic Goods Administration, and by the European Commission as an adjunct to diet to reduce triglycerides for adults with FCS. REDEMPLO is the first and only siRNA treatment approved in these countries to be studied in both clinically diagnosed and genetically confirmed patients living with FCS.
REDEMPLO is designed to suppress the production of apolipoprotein C-III (APOC3), a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting APOC3 with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is self-administered via subcutaneous injection once every three months.
REDEMPLO has been granted Orphan Medicinal Product Designation by the EMA for the treatment of patients with FCS, and Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation by the U.S. FDA for the treatment of patients with FCS and was also granted Breakthrough Therapy designation by the U.S. FDA in severe hypertriglyceridemia.
Sanofi acquired the rights to develop and commercialize REDEMPLO in Greater China, with Arrowhead retaining rights to REDEMPLO in all geographies, outside of Greater China.
For more information about REDEMPLO, visit Our Medicines.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO® (plozasiran) on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing of regulatory approval and the availability of our drugs and drug candidates, including but not limited to plozasiran; and our beliefs and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties including the
safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.
# # #